ijms-logo

Journal Browser

Journal Browser

Special Issue "Adjuvant Therapy for Melanoma: Recent and Future Developments"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editor

Dr. Satoshi Fukushima
E-Mail
Guest Editor
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
Interests: adjuvant therapy; melanoma; immunotherapy

Special Issue Information

Dear Colleagues,

Adjuvant therapy utilizing immune checkpoint blockades (anti-PD-1 Abs) and targeted therapies (BRAF/MEK inhibitors) against melanoma have been approved several years ago. Now these drugs are widely used in many countries. However, the real-world evidence of adjuvant therapy against melanoma is still lacking. For examples, response rates of the recurrent melanoma to the immune checkpoint blockades and targeted therapies are unknown. There is not enough evidence which therapies should be used firstly when the melanoma showed BRAF V600 mutation. Furthermore, neoadjuvant therapies are now tested its efficacy in many trials.

In this Special Issue: Adjuvant Therapy for Melanoma: Recent and Future Developments, the recent evidence of adjuvant therapy for melanoma will be reviewed. And new original research articles for the future developments of adjuvant therapy are going to be presented. Overall, we are confident that this Special Issue will be of interest to the broad readership of the journal. It will provide substantial information covering our current knowledge and future expectations on adjuvant therapy against melanoma.

 

Dr. Satoshi Fukushima
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Adjuvant Therapy
  • Melanoma
  • Immunotherapy
  • Targeted therapy
  • Neoadjuvant therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
microRNAs in the Regulation of Melanogenesis
Int. J. Mol. Sci. 2021, 22(11), 6104; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22116104 - 05 Jun 2021
Viewed by 916
Abstract
Melanogenesis is the process leading to the synthesis of melanin, the main substance that influences skin color and plays a pivotal role against UV damage. Altered melanogenesis is observed in several pigmentation disorders. Melanogenesis occurs in specialized cells called melanocytes, physically and functionally [...] Read more.
Melanogenesis is the process leading to the synthesis of melanin, the main substance that influences skin color and plays a pivotal role against UV damage. Altered melanogenesis is observed in several pigmentation disorders. Melanogenesis occurs in specialized cells called melanocytes, physically and functionally related by means of autocrine and paracrine interplay to other skin cell types. Several external and internal factors control melanin biosynthesis and operate through different intracellular signaling pathways, which finally leads to the regulation of microphthalmia-associated transcription factor (MITF), the key transcription factor involved in melanogenesis and the expression of the main melanogenic enzymes, including TYR, TYRP-1, and TYRP-2. Epigenetic factors, including microRNAs (miRNAs), are involved in melanogenesis regulation. miRNAs are small, single-stranded, non-coding RNAs, of approximately 22 nucleotides in length, which control cell behavior by regulating gene expression, mainly by binding the 3′ untranslated region (3′-UTR) of target mRNAs. This review collects data on the miRNAs involved in melanogenesis and how these miRNAs can modulate target gene expression. Bringing to light the biological function of miRNAs could lead to a wider understanding of epigenetic melanogenesis regulation and its dysregulation. This knowledge may constitute the basis for developing innovative treatment approaches for pigmentation dysregulation. Full article
(This article belongs to the Special Issue Adjuvant Therapy for Melanoma: Recent and Future Developments)
Show Figures

Figure 1

Back to TopTop